Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

narcolepsy 7 - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

narcolepsy 7

MONDO:0013652

Also known as:MOG narcolepsynarcolepsy caused by mutation in MOGnarcolepsy type 7

Overview

Any narcolepsy in which the cause of the disease is a mutation in the MOG gene.

GeneticsAutosomal dominant · MOG (chr 6)

OnsetADULT

Clinical Presentation

Built from Human Phenotype Ontology (HPO) phenotype annotations and GeneReviews clinical descriptions. Features represent findings documented across known cases — not an exhaustive list of possible symptoms.

Features include always present findings: Excessive daytime somnolence and Cataplexy; and very common findings: Obesity. 7 total HPO annotations.

Organ System	Phenotype Count	Example Features
Brain and nerves	2	Hypnagogic hallucination, Excessive daytime somnolence

Genetic Landscape

Assembled from HGNC gene records, ClinGen gene-disease validity evidence, and ClinVar pathogenic variant data. Validity classifications reflect the strength of published evidence linking each gene to this disease.

MOG encodes myelin oligodendrocyte glycoprotein (247 aa). Mediates homophilic cell-cell adhesion. Minor component of the myelin sheath. May be involved in completion and/or maintenance of the myelin sheath and in cell-cell communication

Narcolepsy 7 is associated with mutations in the MOG gene on chromosome 6.

The MOG protein participates in Defective MOGS causes CDG-2b and MOGS removes terminal glucose from Glu3Man9GlcNAc2-CDH1 pathways.

MOG is classified as a druggable target (External Side Of Plasma Membrane category) with score 0.0.

Diagnosis

Genetic testing for MOG is available. Testing is considered confirmatory for diagnosis.

Biomarker and diagnostic research for narcolepsy 7 has been reported in the published literature.

Prognosis

Phenotype severity distribution: 2 always present features, 1 very common feature, 4 common features.

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

No clinical trials have been registered for narcolepsy 7.

140 publications have been identified in PubMed for narcolepsy 7. Research spans Epidemiology / Natural History (34%), Clinical Trial Publication (21%), and Diagnostic / Biomarker (13%).

Research Type	Count	% of Total
Disease patterns and progression	48	34%

Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 11:10 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

OMIM

Online Mendelian Inheritance in Man

OMIM:614250

GARD

Genetic and Rare Diseases Info Center

GARD:15783

Questions for Your Care Team

→Should I pursue genetic testing for MOG, and what would the results mean for my family?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Kisho

narcolepsy 7

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

GARD

Questions for Your Care Team

Questions for Your Care Team

Explore clinical features

Recent Publications

Latest News & Developments

Oveporexton for Narcolepsy Type 1 - Results from Two Phase 3 Trials.

FDA Action Update, January 2026: Approvals, Acceptance, and Clearance | NeurologyLive - Clinical Neurology News and Neurology Expert Insights

narcolepsy 7

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Explore clinical features

Recent Publications

Latest News & Developments

Oveporexton for Narcolepsy Type 1 - Results from Two Phase 3 Trials.

FDA Action Update, January 2026: Approvals, Acceptance, and Clearance | NeurologyLive - Clinical Neurology News and Neurology Expert Insights